Skip to main content

OCD

0
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Jerusalem Pharmaceuticals
Jerusalem PharmaceuticalsIsrael - Ramallah
1 program
P-CIT protocolN/A1 trial
Active Trials
NCT03682913Unknown50Est. Aug 2019
Angeles Therapeutics
Angeles TherapeuticsCA - Los Angeles
1 program
transcranial Direct Current StimulationN/A1 trial
Active Trials
NCT04075890Completed66Est. Jan 2024

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Angeles Therapeuticstranscranial Direct Current Stimulation
Jerusalem PharmaceuticalsP-CIT protocol

Clinical Trials (2)

Total enrollment: 116 patients across 2 trials

NCT04075890Angeles Therapeuticstranscranial Direct Current Stimulation

Arbitration Between Habitual and Goal-directed Behavior in Obsessive-compulsive Disorder: Circuit Dynamics and Effects of Noninvasive Neurostimulation

Start: Jul 2019Est. completion: Jan 202466 patients
N/ACompleted

Personalized Inhibitory Control Training for Compulsive Behavior Change

Start: Jul 2018Est. completion: Aug 201950 patients
N/AUnknown

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.